Impact of delivery method on antiviral activity of phosphodiester, phosphorothioate, and phosphoryl guanidine oligonucleotides in MDCK cells infected with H5N1 bird flu virus


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

We have previously described nanocomposites containing conjugates or complexes of native oligodeoxyribonucleotides with poly-L-lysine and TiO2 nanoparticles. We have shown that these nanocomposites efficiently suppressed influenza A virus reproduction in MDCK cells. Here, we have synthesized previously undescribed nanocomposites that consist of TiO2 nanoparticles and polylysine conjugates with oligonucleotides that contain phosphoryl guanidine or phosphorothioate internucleotide groups. These nanocomposites have been shown to exhibit antiviral activity in MDCK cells infected with H5N1 influenza A virus. The nanocomposites containing phosphorothioate oligonucleotides inhibited virus replication ~130-fold. More potent inhibition, i.e., ~5000-fold or ~4600-fold, has been demonstrated by nanocomposites that contain phosphoryl guanidine or phosphodiester oligonucleotides, respectively. Free oligonucleotides have been nearly inactive. The antiviral activity of oligonucleotides of all three types, when delivered by Lipofectamine, has been significantly lower compared to the oligonucleotides delivered in the nanocomposites. In the former case, the phosphoryl guanidine oligonucleotide has appeared to be the most efficient; it has inhibited the virus replication by a factor of 400. The results make it possible to consider phosphoryl guanidine oligonucleotides, along with other oligonucleotide derivatives, as potential antiviral agents against H5N1 avian flu virus.

Sobre autores

A. Levina

Institute of Chemical Biology and Fundamental Medicine; Novosibirsk State University

Email: zarytova@niboch.nsc.ru
Rússia, Novosibirsk, 630090; Novosibirsk, 630090

M. Repkova

Institute of Chemical Biology and Fundamental Medicine; Novosibirsk State University

Email: zarytova@niboch.nsc.ru
Rússia, Novosibirsk, 630090; Novosibirsk, 630090

B. Chelobanov

Institute of Chemical Biology and Fundamental Medicine; Novosibirsk State University

Email: zarytova@niboch.nsc.ru
Rússia, Novosibirsk, 630090; Novosibirsk, 630090

E. Bessudnova

Institute of Catalysis

Email: zarytova@niboch.nsc.ru
Rússia, Novosibirsk, 630090

N. Mazurkova

Vector State Research Center of Virology and Biotechnology

Email: zarytova@niboch.nsc.ru
Rússia, Koltsovo, Novosibirsk oblast, 630559

D. Stetsenko

Institute of Chemical Biology and Fundamental Medicine

Email: zarytova@niboch.nsc.ru
Rússia, Novosibirsk, 630090

V. Zarytova

Institute of Chemical Biology and Fundamental Medicine; Novosibirsk State University

Autor responsável pela correspondência
Email: zarytova@niboch.nsc.ru
Rússia, Novosibirsk, 630090; Novosibirsk, 630090

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Pleiades Publishing, Inc., 2017